Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Healthcare | Pharmaceuticals | US$656.42B | 62.2x | 0.61 | US$731.94 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.1% Upside | Upgrade to Pro+ | |
J&J | NYSE | Healthcare | Pharmaceuticals | US$365.55B | 26x | -0.45 | US$151.67 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.7% Upside | Upgrade to Pro+ | |
AbbVie | NYSE | Healthcare | Pharmaceuticals | US$309.48B | 73.4x | -6.43 | US$175.05 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.8% Upside | Upgrade to Pro+ | |
Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | US$284.63B | 18.7x | 0.88 | US$64.73 | 5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | OTC Markets | Healthcare | Pharmaceuticals | US$249.35B | 24.6x | -0.91 | US$304.24 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | US$249.35B | 24.6x | -0.91 | US$38.05 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.6% Upside | Upgrade to Pro+ | |
AstraZeneca ADR | NASDAQ | Healthcare | Pharmaceuticals | US$202.45B | 28.7x | 1.69 | US$66.29 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.5% Upside | Upgrade to Pro+ | |
AstraZeneca PLC | OTC Markets | Healthcare | Pharmaceuticals | US$202.45B | 28.7x | 1.69 | US$132.68 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis ADR | NYSE | Healthcare | Pharmaceuticals | US$200.50B | 17.8x | -0.98 | US$107.52 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.4% Upside | Upgrade to Pro+ | |
Novartis | OTC Markets | Healthcare | Pharmaceuticals | US$200.50B | 17.8x | -0.98 | US$104.15 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck&Co | NYSE | Healthcare | Pharmaceuticals | US$199.58B | 11.7x | 0 | US$79.12 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.8% Upside | Upgrade to Pro+ | |
Amgen | NASDAQ | Healthcare | Pharmaceuticals | US$153.93B | 37.5x | -0.98 | US$285.84 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16% Upside | Upgrade to Pro+ | |
Gilead | NASDAQ | Healthcare | Pharmaceuticals | US$129.23B | 270.5x | -3.04 | US$103.62 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.5% Upside | Upgrade to Pro+ | |
Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | US$124.48B | 20.4x | 7.27 | US$51.50 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.1% Upside | Upgrade to Pro+ | |
Pfizer | NYSE | Healthcare | Pharmaceuticals | US$123.98B | 15.4x | 0.06 | US$21.91 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39% Upside | Upgrade to Pro+ | |
Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | US$103.10B | -11.5x | 0.06 | US$50.71 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.9% Upside | Upgrade to Pro+ | |
McKesson | NYSE | Healthcare | Pharmaceuticals | US$86.68B | 31.5x | -24.06 | US$689.36 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.3% Upside | Upgrade to Pro+ | |
Chugai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | US$71.87B | 26.7x | 1.49 | US$21.90 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CSL | OTC Markets | Healthcare | Pharmaceuticals | US$70.84B | 25.4x | 2.41 | US$74.60 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.3% Upside | Upgrade to Pro+ | |
GSK plc DRC | NYSE | Healthcare | Pharmaceuticals | US$68.67B | 20.6x | -0.47 | US$34.64 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25% Upside | Upgrade to Pro+ | |
GSK plc | OTC Markets | Healthcare | Pharmaceuticals | US$68.67B | 20.6x | -0.47 | US$17.32 | 6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zoetis Inc | NYSE | Healthcare | Pharmaceuticals | US$66.61B | 27.3x | 3.46 | US$149.44 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.1% Upside | Upgrade to Pro+ | |
Merck ADR | OTC Markets | Healthcare | Pharmaceuticals | US$56.79B | 18x | -11.64 | US$26.56 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.7% Upside | Upgrade to Pro+ | |
HALEON ADR | NYSE | Healthcare | Pharmaceuticals | US$42.98B | 25x | 0.62 | US$10.05 | 4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.9% Upside | Upgrade to Pro+ | |
Takeda Pharma ADR | NYSE | Healthcare | Pharmaceuticals | US$41.80B | 29.9x | 2.14 | US$13.88 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.6% Upside | Upgrade to Pro+ | |
Takeda Pharma | OTC Markets | Healthcare | Pharmaceuticals | US$41.80B | 29.9x | 2.14 | US$26.13 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Daiichi Sankyo ADR | OTC Markets | Healthcare | Pharmaceuticals | US$40.54B | 24.2x | 0.84 | US$21.88 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cardinal Health | NYSE | Healthcare | Pharmaceuticals | US$31.83B | 24.5x | 0.26 | US$131.77 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.4% Upside | Upgrade to Pro+ | |
Alnylam | NASDAQ | Healthcare | Pharmaceuticals | US$31.02B | -109.4x | -2.87 | US$237.54 | 5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.4% Upside | Upgrade to Pro+ | |
UCB ADR | OTC Markets | Healthcare | Pharmaceuticals | US$28.83B | 23.8x | 0.13 | US$77.48 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Otsuka ADR | OTC Markets | Healthcare | Pharmaceuticals | US$24.41B | 10.7x | 0.07 | US$23.69 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.1% Upside | Upgrade to Pro+ | |
Bayer AG PK | OTC Markets | Healthcare | Pharmaceuticals | US$22.47B | -7.8x | -0.59 | US$5.90 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.9% Upside | Upgrade to Pro+ | |
Royalty Pharma | NASDAQ | Healthcare | Pharmaceuticals | US$18.35B | 16.7x | -0.64 | US$31.95 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33% Upside | Upgrade to Pro+ | |
Biogen | NASDAQ | Healthcare | Pharmaceuticals | US$16.88B | 10.3x | 0.27 | US$115.17 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | OTC Markets | Healthcare | Pharmaceuticals | US$16.49B | US$37.72 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.1% Upside | Upgrade to Pro+ | |||
Astellas Pharma Inc | OTC Markets | Healthcare | Pharmaceuticals | US$15.80B | -39.5x | 0.03 | US$8.88 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.4% Upside | Upgrade to Pro+ | |
Teva ADR | NYSE | Healthcare | Pharmaceuticals | US$14.69B | -11.5x | 0.05 | US$13.46 | 5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shionogi ADR | OTC Markets | Healthcare | Pharmaceuticals | US$12.77B | 11x | 0.94 | US$7.52 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17% Upside | Upgrade to Pro+ | |
Incyte | NASDAQ | Healthcare | Pharmaceuticals | US$10.99B | 354.1x | -3.81 | US$56.87 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.7% Upside | Upgrade to Pro+ | |
Biomarin Pharma | NASDAQ | Healthcare | Pharmaceuticals | US$10.83B | 25.1x | 0.18 | US$56.82 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dr. Reddy’s Labs ADR | NYSE | Healthcare | Pharmaceuticals | US$10.73B | 17.4x | 6.44 | US$13.22 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.8% Upside | Upgrade to Pro+ | |
Viatris | NASDAQ | Healthcare | Pharmaceuticals | US$9B | -14.1x | 0.01 | US$7.54 | 3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ipsen ADR | OTC Markets | Healthcare | Pharmaceuticals | US$8.80B | 21.9x | -0.51 | US$26.77 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shanghai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | US$8.41B | 15.2x | 0.66 | US$6.83 | -11.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sino Biopharma ADR | OTC Markets | Healthcare | Pharmaceuticals | US$8.26B | 33.5x | 0.65 | US$8.79 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CSPC Pharmaceutical Group | OTC Markets | Healthcare | Pharmaceuticals | US$7.81B | 13.4x | -0.54 | US$0.64 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion ADR | OTC Markets | Healthcare | Pharmaceuticals | US$7.61B | 20.4x | 0.42 | US$26.83 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Halozyme | NASDAQ | Healthcare | Pharmaceuticals | US$7.45B | 17.3x | 0.26 | US$60.22 | 4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.5% Upside | Upgrade to Pro+ | |
Corcept | NASDAQ | Healthcare | Pharmaceuticals | US$7.23B | 50.7x | 1.82 | US$68.62 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SINOPHARM ADR | OTC Markets | Healthcare | Pharmaceuticals | US$7.17B | 7.4x | -0.35 | US$11.32 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |